The purpose of this study is to demonstrate the safety and characterize the immunogenicity of AZD2816; AstraZeneca's candidate ChAdOx1 vector vaccine against SARS-CoV-2 variant strain B.1.351
The aim of the study is to assess the safety, and immunogenicity of AZD2816 for the prevention of COVID-19